← Back to Search

Anticoagulant

Low Molecular Weight Heparin for Blood Clot Prevention in Pregnancy

Phase 4
Recruiting
Led By Afshan Hameed
Research Sponsored by University of California, Irvine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Nulliparous or multiparous women with single intrauterine pregnancies who require therapeutic low molecular weight heparin during their pregnancy.
Participants must be age 18 or older.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 hours after injection
Awards & highlights

Study Summary

This trial looks at how split dosing of Lovenox in pregnant women may reduce their risk of blood clots.

Who is the study for?
This trial is for pregnant women aged 18 or older who need blood thinners to prevent clots and have a single baby in the womb. It's not for those under 18, with multiple babies, a history of bad reactions to heparin (HIT), or allergies to enoxaparin.Check my eligibility
What is being tested?
The study tests if taking Lovenox three times daily instead of twice can maintain safer levels in pregnant women due to their body changes. The goal is consistent anticoagulation to reduce clot risks without over-thinning the blood.See study design
What are the potential side effects?
Lovenox may cause bleeding, bruising at injection sites, irritation, and rarely allergic reactions. In pregnancy, it's chosen because it's less likely to harm the baby compared to other blood thinners.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am pregnant and need low molecular weight heparin for treatment.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 hours after injection
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 hours after injection for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Factor Xa levels

Trial Design

1Treatment groups
Experimental Treatment
Group I: Factor Xa levels in pregnant women with therapeutic Lovenox divided into three times a day dosingExperimental Treatment1 Intervention
Therapeutic Lovenox dosing split into three times a day dosing for 5 day. Xa levels a measured.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Enoxaparin
FDA approved

Find a Location

Who is running the clinical trial?

University of California, IrvineLead Sponsor
544 Previous Clinical Trials
1,923,031 Total Patients Enrolled
Afshan HameedPrincipal InvestigatorUniversity of California, Irvine

Media Library

Lovenox (Anticoagulant) Clinical Trial Eligibility Overview. Trial Name: NCT04861103 — Phase 4
Pregnancies Research Study Groups: Factor Xa levels in pregnant women with therapeutic Lovenox divided into three times a day dosing
Pregnancies Clinical Trial 2023: Lovenox Highlights & Side Effects. Trial Name: NCT04861103 — Phase 4
Lovenox (Anticoagulant) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04861103 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)
Afshan B. Hameed, M.D. 2020. "Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04861103.
~4 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top